PIPELINE

Our pipeline

Inmagene is building a robust and portfolio focused on immunology diseases, with the following characteristics:

  • • Best- or first-in-class potentials
  • • Global rights or upside
  • • Strategically balanced between upsides and risks
  • Product*
  • potentials
  • INDICATION
  • Preclinical Phase1 Phase2 Phase3 NDA
  • Best-in-class

    Psoriasis

    Ankylosing Spondylitis

    Takayasu arteritis

    Psoriatic arthritis**

    Uveitis**

  • IMG-016
    First-in-class

    Undisclosed

  • IMG-028
    First-in-class

    Undisclosed

  • IMG-040
    First-in-class

    Undisclosed

  • IMG-004
    Best-in-class

    Undisclosed

  • IMG-007
    First-in-class

    Undisclosed

  • IMG-005
    First-in-class

    Undisclosed

  • IMG-006
    First-in-class

    Undisclosed

  • 12 Programs covering multiple novel targets
    Best-in-class

    Undisclosed

* Chart includes the assets being acquired

**Led by Affibody

Now

By end of 2022

  • Product*:Izokibep
    potentials:Best-in-class
    Preclinical Phase1 Phase2 Phase3 NDA

    INDICATION:Psoriasis

    INDICATION:Ankylosing Spondylitis

    INDICATION:Takayasu arteritis

    INDICATION:Psoriatic arthritis**

    INDICATION:Uveitis**
  • Product*:IMG-016
    potentials:First-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

  • Product*:IMG-028
    potentials:First-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

  • Product*:IMG-040
    potentials:First-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

  • Product*:IMG-004
    potentials:Best-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

  • Product*:IMG-007
    potentials:First-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

  • Product*:IMG-005
    potentials:First-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

  • Product*:IMG-006
    potentials:First-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

  • Product*:12 Programs covering multiple novel targets
    potentials:Best-in-class
    INDICATION:Undisclosed
    Preclinical Phase1 Phase2 Phase3 NDA

* Chart includes the assets being acquired

**Led by Affibody

Now

By end of 2022